Tiziana Life Sciences develops antibody therapies for neurodegenerative and neuroinflammatory diseases from its base in London. TLSA last reported earnings on Fri, Sep 18, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 22 | BTIG | Reiterated | Buy | |
| Sep 3 | BTIG | Initiated | Buy |
Whale Options Flow
90DNo whale options trades in TLSA in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TLSA is in one of them and how their past TLSA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered TLSA in an article yet. Here's the latest on the wider market.
About Tiziana Life Sciences
Tiziana Life Sciences is a biotechnology company based in London, England, that develops treatments for neurodegenerative and neuroinflammatory diseases. Its main candidate, Foralumab, is an antibody being tested as a nasal treatment for conditions such as secondary progressive multiple sclerosis, Alzheimer's disease, and amyotrophic lateral sclerosis. The company is focused on these clinical programs and aims its work at patients with these conditions.
- Headquarters
- London, England, United Kingdom